Rapid increase in innovative product launches, growing adoption of therapeutic antibodies especially in the cost-sensitive markets, rapid approvals by the regulatory authorities with regards to breakthrough therapies have been contributing significantly towards the expansion of antibodies market on a global basis.
Apart from this, rising chronic illnesses due to shifting population as well as rapid increase in longevity along with the low-cost biosimilar antibody therapeutics have been some of the major factors driving antibodies market across the globe. In addition to this, increasing adoption of the diagnostic antibodies, along with leading players adopting several strategies for the expansion of their business and position in the global market will drive the production sales of antibodies.
Related to antibodies market, a research company did conduct a thorough analysis on a global basis. Analysts involved in the development of report named antibodies market have additionally revealed several figures and facts on the global market on an approximate basis. Analysts revealed that antibodies market will be expanding at 12.5% CAGR over the forecast period, 2016-2026, for reaching a valuation of US$ 341,373.6Mn by the end of 2026.
Major players operating in the antibodies market are F. Hoffmann-La Roche Ltd., Eli Lilly and Co., Bristol-Myers Squibb Company, Novartis AG, Takeda Pharmaceutical Company Limited, Sanofi, Biogen Inc. and Johnson & Johnson Services, Inc. among others. Manufacturers and major players in the antibodies market are immensely concentrating on implementing strategies, which would be all-inclusive of innovation and expansion of the product portfolio. This step eventually is expected to be notably lucrative for the end-users on a greater basis.
- Hoffmann-La Roche Ltd. Introduces an Innovative Combination of Studies
According to the current scenario, manufacturers and major players can take note of the matter that F. Hoffmann-La Roche Ltd. has combined Tecentriq with platinum-based and pemetrexed chemotherapy for the purpose of reducing the risks with regards to the diseases that worsen or cause death in the early treatment of people along with the advanced lung cancer.
- Hoffmann-La Roche Ltd. underwent a holistic study named Phase III IMpower132 that helped the in catering to the co-primary endpoint of PFS (progression-free survival) as well as demonstrated combination of the chemotherapy and Tecentriq® that would help in lessening the risks of disease as well as deaths. Patients suffering from advanced lung cancer have been highly beneficial with this new study as it gave them prolonged life compared to earlier research.
Novartis AG Receives Approval for Kymriah®
According to the current scenario, manufacturers and major players can take note of the matter that Novartis AG recently received an approval for Kymriah® by the CHMP (Committee for Medicinal Products for Human Use) of EMA (European Medicines Agency), thereby delivering a positive opinion acclaiming approval. This positive approval has been highly beneficial for the patients suffering from aggressive blood cancers, especially in Europe. Novartis AG is of the point of view that this new therapy will be beneficial for them, in order to cater to the growing demands of adult and pediatric patients on a larger basis.
A sample of this report is available upon request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1330